Stock Traders Purchase High Volume of Call Options on Recursion Pharmaceuticals (NASDAQ:RXRX)

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) was the recipient of unusually large options trading on Friday. Stock investors purchased 22,003 call options on the stock. This represents an increase of 239% compared to the typical volume of 6,490 call options.

Insider Buying and Selling

In related news, CEO Christopher Gibson sold 20,000 shares of Recursion Pharmaceuticals stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of $6.16, for a total transaction of $123,200.00. Following the completion of the sale, the chief executive officer now owns 762,656 shares in the company, valued at approximately $4,697,960.96. This trade represents a 2.56 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Blake Borgeson sold 11,447 shares of the company's stock in a transaction dated Tuesday, September 17th. The shares were sold at an average price of $6.84, for a total transaction of $78,297.48. Following the completion of the transaction, the director now owns 7,109,875 shares in the company, valued at approximately $48,631,545. This trade represents a 0.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 134,235 shares of company stock worth $895,538 in the last ninety days. Insiders own 15.75% of the company's stock.

Institutional Trading of Recursion Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the business. ARK Investment Management LLC increased its holdings in Recursion Pharmaceuticals by 16.4% in the 3rd quarter. ARK Investment Management LLC now owns 32,769,186 shares of the company's stock valued at $215,949,000 after purchasing an additional 4,626,268 shares in the last quarter. Baillie Gifford & Co. grew its position in Recursion Pharmaceuticals by 10.5% in the second quarter. Baillie Gifford & Co. now owns 26,589,936 shares of the company's stock valued at $199,425,000 after acquiring an additional 2,522,132 shares in the last quarter. State Street Corp raised its stake in shares of Recursion Pharmaceuticals by 47.1% during the third quarter. State Street Corp now owns 12,870,272 shares of the company's stock valued at $84,815,000 after purchasing an additional 4,120,685 shares during the period. FMR LLC lifted its position in shares of Recursion Pharmaceuticals by 2.1% during the third quarter. FMR LLC now owns 8,363,530 shares of the company's stock worth $55,116,000 after purchasing an additional 170,810 shares in the last quarter. Finally, Geode Capital Management LLC boosted its stake in shares of Recursion Pharmaceuticals by 13.7% in the third quarter. Geode Capital Management LLC now owns 5,431,911 shares of the company's stock valued at $35,803,000 after purchasing an additional 656,003 shares during the period. Institutional investors and hedge funds own 89.06% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages have weighed in on RXRX. Leerink Partners cut their price target on Recursion Pharmaceuticals from $9.00 to $8.00 and set a "market perform" rating for the company in a report on Tuesday, September 3rd. Jefferies Financial Group dropped their target price on Recursion Pharmaceuticals from $8.00 to $6.00 and set a "hold" rating for the company in a research note on Tuesday, September 3rd. Finally, Needham & Company LLC reissued a "buy" rating and issued a $11.00 price target on shares of Recursion Pharmaceuticals in a research note on Wednesday, November 20th. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, Recursion Pharmaceuticals presently has a consensus rating of "Hold" and a consensus price target of $9.25.

Recursion Pharmaceuticals Trading Up 21.5 %

Shares of NASDAQ RXRX traded up $1.42 during trading on Friday, hitting $8.01. 30,761,670 shares of the company traded hands, compared to its average volume of 6,264,000. The firm has a market capitalization of $2.30 billion, a P/E ratio of -5.28 and a beta of 0.85. The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04. The company has a 50-day moving average price of $6.59 and a 200-day moving average price of $7.35. Recursion Pharmaceuticals has a 1 year low of $5.60 and a 1 year high of $15.74.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.01). The firm had revenue of $26.08 million for the quarter, compared to analysts' expectations of $12.62 million. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. Recursion Pharmaceuticals's revenue was up 147.6% on a year-over-year basis. During the same period last year, the firm posted ($0.43) EPS. On average, equities analysts predict that Recursion Pharmaceuticals will post -1.57 EPS for the current year.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.